A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s DiseaseSatish Keshav, Robert Petryka, S Howaldt et al.|PLoS ONE|2013Cited by 134
IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn’s diseaseJakob Benedict Seidelin, Ole Haagen Nielsen|Clinical & Experimental Immunology|2023Cited by 3